Introduction
Irreversible inhibitors of metabolizing enzymes, as represented by mechanism-based inhibitors, may cause unanticipated adverse effects based on drug-drug interactions (DDIs) due to affecting the blood concentration of a co-administered drug for a long time because they continue to inhibit the enzyme until the inactivated enzyme is replaced by a newly synthesized one (Ito et al., 1998; Venkatakrishnan et al., 2003) . Guidance from the Ministry of Health, Labour and Welfare in Japan 112.pdf) all stipulate the need to evaluate mechanism-based inhibition (MBI).
In vitro-in vivo extrapolation (IVIVE) methods to predict clinical DDI from in vitro inhibition data are therefore important for drug development. Although we recently reported that the prediction method for competitive inhibitors using an in vivo inhibition constant (Ki) and a physiologically-based pharmacokinetic (PBPK) model was more accurate than the conventional method (Kato et al., 2008) , there were inhibitors causing DDI which could not be predicted successfully in the manner of competitive inhibitors, and one of the possible reasons is that they we reported that following the pretreatment of mibefradil, a mechanism-based inhibitor of CYP3A, at 6 mg/kg and 12 mg/kg 24 h before the oral administration of midazolam (MDZ), a probe substrate, in rats, the maximum plasma concentration (C max ) and the area under concentration-time curve (AUC) of MDZ were significantly elevated in comparison with the control (Sekiguchi et al., 2008) .
Therefore, we aimed to quantitatively predict the DDI observed in rats using a PBPK model from in vitro inactivation parameters in this study. Although it was suggested that MDZ was mainly metabolized by CYP3A in rats (Sekiguchi et al., 2008) , not only CYP3A but also CYP2C isozymes were reported to produce metabolites of MDZ in rats (Chovan et al., 2007) . Thereby, there is a possibility that CYP2C isozymes are also inactivated by mibefradil. How much metabolizing enzymes are involved in eliminating a probe and the potential of an inhibitor to inactivate each enzyme are very important factors in the analysis of the DDI. For more precise predictions, those
rrCYP3A2, rrCYP2C11, and rrCYP2C13. The enzymes were diluted by 0.1 M potassium phosphate buffer (pH 7.4) at 20 pmol/ml of final concentration. Protein concentrations of incubation mixtures were adjusted at 0.2 mg/ml by adding control microsomes. After addition of NADPH to the enzyme solutions at 1 mM of final concentration and pre-incubation at 37°C for 5 min, the reaction was started by adding MDZ at 200 nM of final concentration (total volume of the reaction mixture: 900 μL). MDZ concentration in reaction mixtures, 200 nM, was thought to be considerably lower than K m values of CYP3A2 and CYP2C11 on MDZ metabolism (Carr et al., 2006; Chovan et al., 2007) . In vivo study. Mibefradil dihydrochloride was dissolved in water at 6 mg/ml or 12 mg/ml as the mibefradil concentration. Mibefradil was administered orally at 1 ml/kg to rats under a fed condition (n=4). Blood samples were collected from the jugular vein at 0.17, 0.5, 1, 2, 4, 6, 8, and 24 h after administration of mibefradil and immediately centrifuged to obtain plasma samples. The plasma samples were kept at approximately -80°C until analysis.
Analysis of MDZ metabolites and mibafradil. The concentrations of 1'-hydroxymidazolam, 4-hydroxymidazolam, and mibefradil were measured by high-performance liquid chromatography-electrospray tandem mass spectrometry.
For the in vitro studies, the samples with acetonitrile containing the IS added were centrifuged, and 10 μL of supernatants were injected to a Quattro ΙΙ tandem mass spectrometer (Micromass Ltd., contribution ratio was estimated by multiplying the metabolic rate of MDZ in each microsomes expressing the recombinant CYP by the abundance ratio of each isozyme in rat liver. The metabolic rate of MDZ was represented by the sum of the production rates of the two major metabolites, 1'-hydroxymidazolam and 4-hydroxymidazolam, to which MDZ was reported to be almost mainly metabolized in rats (Ghosal et al., 1996b) . The production rate was estimated by dividing the metabolite concentration in a linear phase of metabolite concentration-incubation time plot by the enzyme concentration and incubation time. The abundance ratio of each isozyme was found in published data (Imaoka et al., 1990; Ghosal et al., 1996a; Shimada et al., 1997) .
Kinetic parameters of enzyme inactivation. For incubations in recombinant enzymes and RLMs
with or without mibefradil, the natural logarithm of the percentage of remaining activity involved in the production of 1'-hydroxymidazolam or 4-hydroxymidazolam was plotted against the preincubation time. The observed inactivation rate constants (k obs ) were determined from the slopes of the initial linear decline in activity (Silverman, 1995) . The net value of k obs (k' obs ) was calculated by subtracting the k obs at zero of the inhibitor concentration from the k obs at each concentration of the inhibitor. Silverman reported that two principal constants useful in describing MBI, k inact and K I,app , can be obtained experimentally (Silverman, 1995) . 
where I is the initial concentration of the inhibitor (Silverman, 1995) . For the Equation 1, it was assumed that there is negligible change in I in the incubation period. For MDZ:
Quantitative prediction of the in vivo DDI
For mibefradil:
This article has not been copyedited and formatted. The final version may differ from this version. hepatic vein are equal to those in the liver at equilibrium (well-stirred model). Also, gastrointestinal absorption is assumed to be described by a first-order rate constant. Plasma concentrations of MDZ from the literature (Sekiguchi et al., 2008) and mibefradil measured by the procedure described above when they were administered solely (E act = E 0 ) were fitted into the PBPK model described above, and CL int,S, , CL int,I , k a,S , k a,I , V sys,S , and V sys,I were calculated using SAAM II ver. 1.2 software (Saam Institute, Inc., Seattle, WA).
The differential equation for E act can be described as follows:
where k deg represents the degradation rate constant (turnover rate constant) of enzyme; R 1 and R 2 represent the contribution ratio of CYP3A2 and CYP2C11, respectively; k inact,1 and k inact,2 represent the k inact of mibefradil against CYP3A2 and CYP2C11, respectively; K I,app,1 and K I,app,2 represent the K I,app of mibefradil against CYP3A2 and CYP2C11, respectively. In the absence of mibefradil, the enzyme content in the liver is at steady state and the degradation rate (k deg × E 0 ) is equal to the synthesis rate, which was assumed to be unaffected by mibefradil.
The physiological parameters of rat and pharmacokinetic parameters of MDZ and mibefradil used in the simulation are listed in Table 1 . Using SAAM II and kinetic parameters for enzyme inactivation obtained in in vitro studies, the above differential equations were numerically solved to This article has not been copyedited and formatted. The final version may differ from this version. simulate the time courses of the active enzyme content in the liver (E act ) and MDZ concentration in blood. According to the literature, the dosing route and regimen for the DDI study of MDZ and mibefradil were scheduled as follows. Twenty four hours after oral administration of mibefradil at 6 mg/kg or 12 mg/kg, MDZ was administered orally at 10 mg/kg (Sekiguchi et al., 2008) . Simulated values of MDZ concentrations, C max , and AUC were compared with the observed data.
Results
Contribution ratios of CYP isozymes involved in MDZ metabolism. Contribution ratios of CYP isozymes estimated using the production rate of MDZ metabolites in recombinant CYPs and the abundance ratios in the liver taken from publication data are shown in Table 2 . CYP3A2 exists in rat liver to a lesser extent than CYP2C11, but metabolized MDZ much more rapidly, suggesting that CYP3A2 mainly contributes to MDZ metabolism, and CYP2C11 only slightly contributes.
Metabolites produced by CYP2C13 were not observed.
Inactivation parameters of mibefradil against rrCYP3A2, rrCYP2C11, and RLM. Effects of mibefradil concentration and preincubation time on 4-or 1'-hydroxylation of MDZ by rrCYP3A2, rrCYP2C11, and RLM are shown in Figure 2 . In all enzyme sources, the production of metabolites decreased according to mibefradil concentration and preincubation time, suggesting that time-dependent inhibition was observed. K I,app and k inact values of mibefradil against each enzyme are shown in Table 3 . The k inact in all enzymes were large values and almost similar, whereas the
values 10 or 30 min after administration were lower than the observed values. The k a and V sys values of mibefradil estimated by the fitting were almost similar between 6 mg/kg and 12 mg/kg (Table 1) .
However, the CL int values at 6 mg/kg and 12 mg/kg were estimated to be 75.6 and 49.4 l/h, suggesting a non-linearity.
Prediction of DDI caused by MBI. Previously, as a result of the oral administration of mibefradil at 6 mg/kg or 12 mg/kg 24 h before oral administration of MDZ in rats, it was shown that plasma concentrations of MDZ with a pretreatment of mibefradil were elevated compared with the control (Sekiguchi et al., 2008) . Prediction of the DDI was conducted using the model represented in Figure   1 . The prediction showed that active content of CYP3A2 was significantly reduced by administering mibefradil, although that of CYP2C11 was reduced less than or comparable to 20% even at 12 mg/kg of mibefradil (Figure 4 ). Active content of the total enzymes in the liver was predicted at a time-profile similar to CYP3A2.
Observed and predicted plasma concentrations of MDZ with and without co-administration of mibefradil are shown in Figure 5 , and C max and AUC values in those groups are shown in Table 4 .
The model predicted that co-administration of mibefradil would elevate MDZ concentration, and the predicted increases in MDZ concentrations, C max , and AUC resulting from the co-administration closely corresponded to the observed values.
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Discussion
We thought that when a decision on the development of candidate drugs possessing a potential for MBI is being made, an evaluation of in vivo MBI in animals coupled with an evaluation of in vitro DDI using human enzymes would increase the levels of confidence for that decision. We therefore previously verified whether an inhibitor which exhibits MBI in humans also gives rise to DDI in rats by ascertaining that pretreatment with mibefradil significantly elevated C max and AUC values of orally-administered MDZ compared to the control (Sekiguchi et al., 2008) . In this study, to further increase confidence levels, we aimed to quantitatively predict the DDI observed in rats from in vitro inactivation data.
To predict DDI caused by the inhibition of metabolism, the contribution ratios of enzymes involved in the metabolism of an interacted drug are critical factors to be considered. Although it was reported by us and other laboratories that MDZ was mainly metabolized by CYP3A in rats (Kose et al., 2005; Sekiguchi et al., 2008) , CYP2C isozymes were also reported to produce metabolites of MDZ (Chovan et al., 2007) . CYP3A4 is the most highly-expressed CYP isozyme in human liver (Shimada et al., 1994) , whereas in rat liver CYP2C11 is highly-expressed (Imaoka et al., 1990) , and CYP2C13 was reported to be comparable to CYP3A2 (Imaoka et al., 1990) . So, first, the contribution ratios of CYP3A2, 2C11, and 2C13 involved in MDZ metabolism were evaluated using the production rate of metabolites in recombinant CYPs and the abundance ratios in rat liver This article has not been copyedited and formatted. The final version may differ from this version. Imaoka et al., 1990; Ghosal et al., 1996a; Shimada et al., 1997) . Because it was reported that the major metabolites were 4-hydroxymidazolam and 1'-hydroxymidazolam in rats as well as in humans (Ghosal et al., 1996b) , the production rates of these two metabolites were used for the estimation.
The result showed that production rate by CYP3A2 was extremely large, but no metabolites by CYP2C13 were observed (Table 2 ). Compared to the results reported by Chovan, the rate by CYP3A2 was relatively more rapid in our study. However, the result that CYP3A2 and 2C11
preferentially produced 4-hydroxymidazolam and 1'-hydroxymidazolam, respectively, was identical.
Due to the metabolic rate, CYP3A2 was suggested to be the major enzyme involved in MDZ metabolism despite it being less abundant in the liver.
Next, the potential of mibefradil to exert MBI on CYP3A2 and CYP2C11 was evaluated. Because mibefradil was reported to induce MBI against CYP3A4 and CYP2C8 in humans (Polasek et al., 2004) , it was considered likely that isozymes other than CYP3A in rats are also inactivated by mibefradil. As a result of evaluating the inhibitory activity of mibefradil on MDZ metabolism using
2 2 mibefradil caused MBI against CYP3A2 more intensely. Additionally, the parameters of mibefradil against RLM were very similar to those against CYP3A2. This result appears to indicate that MBI by mibefradil was mainly dependent on the inactivation of CYP3A2.
Next, to verify whether prediction of in vivo DDI from in vitro data is possible, a predictive model for MBI was constructed. For the prediction, we used a PBPK model which represents change in inhibitor and substrate concentrations over time and has the advantage of a detailed DDI analysis ( Figure 1 ) (Ito et al., 2003) . To construct the PBPK model, plasma concentrations of an inhibitor, mibefradil, administered solely were measured ( Figure 3) . As a result of fitting calculations of the observed concentrations into the PBPK model, CL int value at 12 mg/kg was smaller than that at 6 mg/kg, in brief non-linearity in the elimination phase was observed (Table 1 ). The phenomenon that plasma concentrations of mibefradil rose more than the dosage ratio had been observed in humans previously (Welker et al., 1998) . According to a report on the metabolic pathway of mibefradil, oxidative metabolites were major (Wiltshire et al., 1997b) . Therefore, this non-linear pharmacokinetics appeared to occur due to the auto-inactivation of metabolism of mibefradil by MBI. Because of the non-linearity, pharmacokinetic parameters of mibefradil were estimated and used for the prediction separately at each dose. Plasma concentrations of mibefradil calculated by the fitting were well consistent with the observed values except for the initial period after administration.
Thus, it was judged that there was no problem with the prediction of the DDI where MDZ was
administered 24 h after mibefradil administration.
Then, we predicted the DDI by inserting the in vitro parameters into the PBPK model constructed.
It was defined that CYP3A2 and CYP2C11 contribute to MDZ metabolism at the contribution ratios shown in Table 2 , and inactivation of the two isozymes occurs according to the inactivation parameters shown in Table 3 . In the model, mibefradil administered at 6 mg/kg or 12 mg/kg was predicted to reduce active CYP content in the liver (Figure 4) , and increase plasma concentrations of MDZ ( Figure 5 ), consequently causing MBI. Predicted increases in C max and AUC of MDZ with the co-administration of mibefradil closely corresponded to the observed values (Table 4 ). In the above prediction, it was assumed that intestinal metabolism is not affected by mibefradil administration, because it was reported that F a,S ×F g,S of MDZ was relatively high, about 0.8 in rats (Higashikawa et al., 1999; Kuze et al., 2009) . If it was assumed that intestinal metabolism was entirely inhibited by mibefradil (F a,S ×F g,S of MDZ = 1), C max and AUC of MDZ co-administered with mibefradil were predicted to increase up to about 30% (196 ng/ml and 291 ng×h/ml at 6 mg/kg of mibefradil, 344 ng/ml and 524 ng×h/ml at 12 mg/kg of mibefradil, respectively) compared with prediction results without inhibition of intestinal metabolism. Although in this study the prediction in which intestinal metabolism was not inhibited was closer to the observed results, it may be desirable to predict DDI both with and without the intestinal metabolism inhibited because a methodology for predicting inactivation of intestinal enzymes has not been established. However, in
this study, it was thought that both prediction results would almost correspond to the observed data.
Additionally, in the prediction of MBI, k deg is a very important factor. Because rigorous values of k deg of rat CYP isozymes have not been clear yet, we assumed that k deg values of rat CYPs are the same.
Under such an assumption, the prediction gave results close to the observed data. These results demonstrate that construction of a predictive model using the PBPK model in detail would enable a precise prediction of DDI caused by MBI. As shown above, verification that the results predicted from in vitro data correspond to the in vivo data in animals will increase confidence in results predicted by the same method in humans.
In this study, since two isozymes, CYP3A2 and CYP2C11, contribute to MDZ metabolism, their contribution ratios and inactivation parameters were inserted into the predictive model. As far as we know, this is the first study in which inserting inactivation of multiple isozymes into the predictive model of DDI using a PBPK model was tried. Maybe due to the difference in K I,app values, active CYP3A2 content was predicted to be decreased considerably by mibefradil, whereas active
2 5 metabolism would be meaningful for a more accurate prediction. Since there are many drugs metabolized by multiple enzymes in clinic, this approach is expected to contribute to improved prediction accuracy.
In conclusion, it was suggested that the DDI between MDZ and mibefardil in rats was caused by inactivation of CYP3A2 mainly, and CYP2C11 slightly. As a result of predicting DDI using the 
Figure 3
Plasma concentrations of mibefradil after oral administration at 6 mg/kg and 12 mg/kg in rats.
Closed triangles and squares represent observed values at 6 mg/kg and 12 mg/kg, respectively.
Dashed and solid lines represent simulated values at 6 mg/kg and 12 mg/kg by the fitting calculation, respectively.
Figure 4
This article has not been copyedited and formatted. The final version may differ from this version. Predicted change in active CYP contents after the administration of mibefradil at 6 mg/kg (A) and 12 mg/kg (B) in rats. Dashed, thin, and heavy lines represent the change in CYP3A2, CYP2C11 and total CYP contents, respectively. This article has not been copyedited and formatted. The final version may differ from this version. b Contribution ratio was calculated using the production rate of the two metabolites and the abundance ratio.
This article has not been copyedited and formatted. The final version may differ from this version. Table 4 Comparison of observed and predicted C max and AUC values of midazolam in rats with or without pretreatment with mibefradil
Mibefradil was administered orally 24 h before midazolam administration. Predicted value was evaluated using the model and parameters in Figure 1 and 
